How people undergoing genomic sequencing interpret and react to varied secondary findings with limited actionability
Authors:
- 4 March 2025
- journal article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 22 (2) , 93-101
Abstract
To investigate patient reactions to and understanding of secondary genomic findings with limited to no medical actionability (LMA-SFs) from diagnostic genome sequencing. We analyzed LMA-SFs returned to 47 adults who elected to receive a broad set of these results from 6 categories. Findings indicated elevated risk (reportable/positive) or not (negative/normal). Most participants (N = 43) also completed surveys to report their distress, decision regret, expected health anxiety, and whether and how they perceived results as reassuring or troubling. Most participants received some reportable LMA-SFs for common risk, pharmacogenetic, and carrier status variants. Fewer received reportable APOE haplotype or monogenetic condition variants. None received results indicating high risk for severe neurological disease. Overall, participants (76.7% female, 97.7% White) had low distress, decision regret, and expected health anxiety. None described negative/normal findings as troubling. However, their interpretations of reportable/positive results varied. Even within the same result type, some participants found them troubling, while others found them reassuring based on their perception of the results' utility. Participants' short-term well-being was not reduced by receiving LMA-SFs. Their interpretations suggested varied personal utilities and the need for post-test resources to aid understanding of these types of results and their health significance.Keywords
Funding Information
- National Institutes of Health (U01HG006487)
This publication has 40 references indexed in Scilit:
- ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2023
- A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of ‘moderate risk’ genetic results in a population breast cancer screening trialJournal of Genetic Counseling, 2022
- The long‐term impact of receiving incidental findings on parents undergoing genome‐wide sequencingJournal of Genetic Counseling, 2022
- Experiences and lessons learned by genetic counselors in returning secondary genetic findings to patientsJournal of Genetic Counseling, 2020
- Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literatureEuropean Journal of Medical Genetics, 2019
- Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing PilotThe American Journal of Human Genetics, 2018
- The past, present and future of service delivery in genetic counseling: Keeping up in the era of precision medicineAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2018
- Patients' views on incidental findings from clinical exome sequencingApplied & Translational Genomics, 2015
- Reporting Incidental Findings in Clinical Whole Exome Sequencing: Incorporation of the 2013 ACMG Recommendations into Current Practices of Genetic CounselingJournal of Genetic Counseling, 2014
- Attitudes of Genetics Professionals Toward the Return of Incidental Results from Exome and Whole-Genome SequencingThe American Journal of Human Genetics, 2014